Supplemental material
Open access
2,782
Views
6
CrossRef citations to date
0
Altmetric
Original Research
A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST)
Christopher Wynnea New Zealand Clinical Research, Christchurch, New ZealandView further author information
, Christian Schwabeb New Zealand Clinical Research, Auckland, New ZealandView further author information
, Charlotte Lemechc Scientia Clinical Research, NSW, AustraliaView further author information
, Heimo Stroissnigd Alvotech Germany GmbH, Jülich, GermanyView further author information
, Roshan Diase Alvotech Swiss AG, Zürich, SwitzerlandView further author information
, Joanna Sobierskae Alvotech Swiss AG, Zürich, SwitzerlandView further author information
, Eric Guenzid Alvotech Germany GmbH, Jülich, GermanyView further author information
, Hendrik Ottod Alvotech Germany GmbH, Jülich, GermanyView further author information
, Abid Sattarf Alvotech UK Ltd, London, UKView further author information
, Richard Kayg RK Statistics Ltd, Bakewell, UKView further author information
, Halimu N. Haliduolad Alvotech Germany GmbH, Jülich, GermanyView further author information
& Fausto Bertie Alvotech Swiss AG, Zürich, SwitzerlandCorrespondence[email protected]
View further author information
show allView further author information
Pages 965-976
|
Received 21 Dec 2021, Accepted 25 Jan 2022, Published online: 10 Feb 2022
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.